[Clinical significance of the short-term incubation test for the therapy of metastatic breast cancer]. / Klinische Bedeutung des Kurzzeitinkubationstests für die Therapie des metastasierten Mammakarzinoms.

Between January 1978 and October 1980 97 tissue samples of histologically verified carcinoma of the breast were received for performance of the short-term incubation test. 25 tumour samples could not be prepared as cell suspension sufficient for testing. Among the 72 performed tests there were 9 with stimulation of 3H-uridine uptake by doxorubicin. Thus only 63 tests could be evaluated. Results were correlated with clinical data of the patients. No significant correlations could be established between tumour stage at time of diagnosis, age, menopausal state, receptor state, and the test result. There was also no differentiation between favourable and unfavourable prognoses as regards free interval and rate of survival. A correlation between results of tests and success or failure of cytostatic treatment could not be ascertained.

[3H-thymidine incorporation under endocrine influence and hormone receptor content of human mammary carcinoma (author's transl)]. / 3H-Thymidin-Inkorporation unter endokrinem Einfluss und Hormonrezeptorgehalt menschlicher Mammakarzinome.

The effect of medroxyprogesterone acetate, oestradiol-17 beta and testolactone on 3H-thymidine incorporation in human mammary carcinoma was studied in vitro. 54% of the tumours reacted to medroxyprogesterone, while testolactone and oestradiol-17 beta changed 3H-thymidine incorporation in 45.1 and 41.3%, respectively. Both inhibition and the in vivo undesirable stimulation of 3H-thymidine incorporation was observed. No relation could be established between oestrogen receptor content and reaction of the mammary carcinoma to oestradiol-17 beta. On the other hand, the gestagen receptor content and the reaction of the mammary carcinoma to medroxyprogesterone acetate correlated significantly (P < 0.001). This underlines the increasing significance of the gestagen receptor in the selective endocrine treatment of mammary carcinoma.